Media Centre

Latest Uploads

29 Jun 2017 - Press Release

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

      The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting thi...

Read more
13 Jun 2017 - News

EBE Webinar: IP and its crucial role in bringing innovative medicines to patients

20 June 2017 from 16H30 - 17H30 CET Europe has good science and sound Intellectual Property (IP) policies in place. These IP policies and other incentive offered by legislation when medicines are d...

Read more
02 Jun 2017 - Press Release

Reinventing the European Advanced Therapies Sector: An Interview with Eduardo Bravo

In 2009 TiGenix was the first company in Europe to gain the newly created advanced therapy medicinal product (ATMP) authorisation for its ChrondroCelect®, a somatic cell treatment product which repla...

Read more

Press Releases

29 Jun 2017

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide....

Read more
View All

Position Papers

09 Mar 2017

EBE, EFPIA and IFPMA position paper “Considerations for physicians on switching decisions regarding biosimilars”

Switching describes a physician's decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients...

Read more
12 Oct 2016

EBE Position Paper ” A Risk-based Approach to Setting Sterile Filtration Bioburden Limits”

As part of the submission supporting the request for a marketing authorisation, medicines must demonstrate that they are of appropriate quality, which often includes a demonstration of sterility.  B...

Read more
View All

Publications

10 May 2017

What pricing and reimbursement policies to use for off-patent biologicals? – Results from the second EBE biological medicines policy survey

Objective: Biosimilar policies with a focus on uptake have received a lot of attention at national and regional level in the last few years. It is now 10 years since the first biosimilar was approved in the European Union, but do policies in the Member States take the differences between biological medicines and small-molecule generics into account? To map the policy landscape in Europe, European Biopharmaceutical Enterprises (EBE) has conducted a second round of its descriptive survey of pricing and reimbursement policies for off-patent biologicals....

Read more
15 Mar 2017

Biosimilar product labels in Europe: what information should they contain?

To discuss current labelling of biosimilars in Europe, the European Biopharmaceutical Enterprises (EBE) and the European Association for Bioindustries (EuropaBio) held a multi-stakeholder workshop on...

Read more
View All

Videos

View All

Photos

View All
Glossary
Links